

DAFTAR PUSTAKA

1. Hsu CK, Yang HS, McGrath JA. Genetics of scars and keloid. Dalam: Ogawa R, editor. Total Scar Management. Tokyo: Springer. 2020:47-53.
2. Binic I. Keloids and Hypertrophic Scars. In: Katsambas AD, editors. European Handbook of Dermatological treatment. Berlin:Springer-verlag Berlin Heidelberg. 2015:455-464.
3. Andisi R, Suling P, Kapantow M. Profil Keloid di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado Periode Januari 2011 – Desember 2015. Jurnal e-Clinic (eCl). 2016;4(2).
4. Birawati S, Asri E. Keloids profile in the Dermatovenerology Clinic of RSUP Dr . M . Djamil Padang Indonesia from January 2014 to December 2018. International Journal of Pharm Tech Research. 2020;13(04):383-387.
5. Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. International Journal of Molecular Sciences. 2017;18(606):1-10.
6. Anaba EL, Akwara I, Johnson O. A Prospective Study of Pattern of Keloid and Number of Intralesional Triamcinolone Acetonide Injections in A Community Based Dermatology Clinic in Lagos, Nigeria. International Journal of Research in Dermatology. 2019;5(4):760-764.
7. Belie O, Ugburo AO, Mafikoya BO. Demographic and clinical characteristics of keloids in an urban center in Sub-Sahara Africa. Nigerian Journal of Clinical Practice. 2019;22:1049-1054.
8. Mishra B, Arora C. Epidemiology of keloids and hypertrophic scars in a Tertiary Care Teaching Hospital of Northern India. International Journal of Scientific Research. 2020;10(2):54-55.
9. Bijlard E. Wound healing and scarring. In: Hovios, editor. Less Is More in Keloid Disease. Woensdag: Erasmus University Rotterdam. 2017.
10. Wolfram D, Tzankov A, Pulzi P, Katzer HP. Hypertrophic scar and keloids—a review of their pathophysiology, risk factor and therapeutic management. Dermatologic Surgery. 2009;35:171-181.
11. Betarbet U, Blalock TW. Keloids: a review of etiology, prevention and treatment. Journal of Clinical and Aesthetic Dermatology. 2020;13(2):33-43.
12. Broek LJ, Limandjaja GC, Niessen FB, Gibbs S. Human hypertrophic and keloid scar models: principles , limitations and future challenges from a tissue engineering perspective. 2014:382-386.
13. Motoki THC, Isoldi FC, Filho AG, Ferreira LM. Keloid negatively affects body image. Burn. 2018:1-5.
14. Olaitan PB, Olabanji JK, Oladele, Oseni GA. Symptomatology of Keloids in Africans. Sierra Leone Journal of Biomedical Research. 2013;5(1):29-33.
15. Bijlard E, Kouwenberg C, Timman R, Hovius S, Busschbach J, Mureau M. Burden of Keloid Disease: A Cross sectional Health-related Quality of Life Assessment. Acta Dermato-Venereologica. 2017;97:225-229.
16. Kouwenberg C, Bijlard E, Timman R, Hovius S, Busschbach J, Mureau M. Emotional Quality of Life Is Severely Affected by Keloid Disease : Pain and Itch Are the Main Determinants of Burden. Plastic and Reconstructive Surgery. 2015:1-3.

17. Nangole FW, Agak GW. Keloid pathophysiology: fibroblast or inflammatory disorders ? JPRAS Open. 2019;22:44-54.
18. Bae J, Kim N, Shin Y, Kim SY, Kim YJ. Activity of catechins and their applications. 2020;4(8):1-10.
19. Zhang Q, Kelly AP, Wang L, French SW, Tang X, Duong HS, et al. Green Tea Extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/Akt signaling pathways. Journal of Investigative Dermatology. 2006;126:2607-2613.
20. Park G, Yoon BS, Moon J, Kim B, Jun EK, Oh S, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. Journal of Investigative Dermatology. 2008;128:2429-2441.
21. Ud-din S, Foden P, Mazhari M, Al-Habba S, Baguneid M, Paus SB, et al. A double-blind , randomized trial shows the role of zonal priming and direct topical application of epigallocatechin-3-gallate in the modulation of cutaneous scarring in human skin. Journal of Investigative Dermatology. 2019;139:1680-1690.
22. Hosen N. Profil sistem usaha pertanian gambir di Sumatera Barat. Jurnal Penelitian Pertanian Terapan. 2017;17(2):124-131.
23. Yeni G, Syamsu K, Mardiyati E, Muchtar H. Penentuan teknologi proses pembuatan gambir murni dan katekin terstandar dari gambir asalan. Jurnal Litbang Industri. 2017;7(1):1-10.
24. Anjarsari IRD. Katekin teh Indonesia: prospek dan manfaatnya. Jurnal Kultivasi. 2016;15(2):99-106.
25. Hilmi HL, Rahayu D. Artikel tinjauan: aktivitas farmakologi gambir (*Uncaria gambir Roxb.*). Farmaka. 2018:134-141.
26. Zakiah K. Uji efek antiproliferatif campuran senyawa eugenol dan isolat katekin gambir (*Uncaria gambier, Roxb*) dari fase etil asetat terhadap kultur sel kanker serviks (*HeLa cell line*). Universitas Islam Negeri Syarif Hidayatullah Jakarta. 2011.
27. Perdanasari AT, Lazzeri D, Su W, Zheng Z, Ke 1, Min P dkk. Recent Developments in the Use of Intralesional Injections Keloid Treatment. Archive of Palstic Surgery. 2014;41(6):620-629.
28. Sharma JR, Lebeko M, Kidzeru EB, Khumalo NP, Bayat A. In vitro and ex vivo models for functional testing of therapeutic anti-scarring drug targets in keloids. Advances In Wound Care. 2019;8(12):655-670.
29. Lebeko M, Khumalo NP, Bayat A. Multi-dimensional models for functional testing of keloid scars: in silico, in vitro, organoid, organotypic, ex vivo organ culture and in vivo models. Wound Repair and Regeneration. 2019;27:298-308.
30. Meerloo J Van, Kaspers GJL, Cloos J. Cell sensitivity assays : the MTT assay. In: Ian A C, editor. Cancer cell culture: methods and protocols, second edition. Jerman: Springer Science+Business Media. 2011:237-245.
31. Präbst K, Engelhardt H, Ringgeler S. Basic colorimetric proliferation assays: mtt, wst, and resazurin konstantin. In: Daniel F. Gilbert, Oliver Friedrich, editors. Cell viability assays: methods and protocols, methods in molecular biology. Jerman: Springer Science & Business Media. 2017:1-17.

32. Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. *Cold Spring Harb Protoc.* 2018:469-472.
33. Martinotti S, Ranzato E. Scratch wound healing assay. *Methods in Molecular Biology.* 2019:1-5.
34. Mouritzen MV, Jenssen H. Optimized scratch assay for in vitro testing of cell migration with an automated optical camera. *Journal of Visualized Experiments.* 2018;(8):1-6.
35. Thareja S, Kundu RV. Keloids and hypertrophic scarring. In: Vashi NA, Maibach HI. *Dermatoanthropology of Ethnic Skin and Hair.* Switzerland: Springer International Publishing. 2017:233-255.
36. Alavi A, Kirsner RS. Wound Healing. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al, editors. *Fitzpatrick's Dermatology in General Medicine* 9th ed. New York: McGraw-Hill. 2019:2700-2717.
37. Smith N, Cha KB, Christopher B. Perioperative Considerations in Dermatologic Surgery. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al, editors. *Fitzpatrick's Dermatology in General Medicine* 9th ed. New York: McGraw-Hill. 2019:3706-3725.
38. Shaheen A. Comprehensive review of keloid formation. *Clinical Research in Dermatology Open Acces.* 2018;4(5):1-18.
39. Onyenirionwu E, Agu A. Keloids: a review. *Journal of Medical Investigations and Practice.* 2015:24-29.
40. Marshall CD, Hu MS, Leavitt T, Barnes LA, Lorenz HP, Longaker MT. Cutaneous scarring: basic science, current treatments, and future directions. *Advances in Wound care.* 2016;00(00):1-17.
41. Kouotou EA, Nansseu JR, Guissana EO, Menye CRM, Akpadjan F, Tounkara TM, et al. Epidemiology and clinical features of keloids in Black Africans: a nested case-control study from Yaounde Cameroon. *International Journal of Dermatology.* 2019:1-6.
42. Noishiki C, Hayasaka Y, Ogawa R. Sex differences in keloidogenesis: an analysis of 1659 keloid patients in Japan. *Dermatology and Therapy (Heidelb).* 2019;9(4):747-754.
43. Shih B, Bayat A. Genetics of keloid scarring. *Archive of Dermatological Research.* 2010:319-339.
44. Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and hypertrophic scars : a spectrum of clinical challenges. *American Journal of Clinical Dermatology.* 2016.
45. Tsai CH, Ogawa R. Keloid research: current status and future directions. *Scars, Burns & Healing.* 2019;5:1-8.
46. Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis – keloids and hypertrophic scars may be vascular disorders. *Medical Hypotheses.* 2016;96:51-60.

47. Kim H, Hwang S, Lim K, Jung Y, Ahn S, Song JK. Recurrent auricular keloids during pregnancy. *Archives of Plastic Surgery*. 2013;70-72.
48. Arima J, Huang C, Rosner B, Akaishi S, Ogawa R. Hypertension: a systemic key to understanding local keloid severity. 2015:213-221.
49. Kilmister EJ, Paterson C, Brasch HD, Davis PF, Tan ST. The role of the renin-angiotensin system and vitamin d in keloid disorder - a review. *Frontiers in Surgery*. 2019;6:1-12.
50. Fang Q, Wang X, Zhao W, Ding S, Shi B, Xia Y, et al. Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF- β 1 pathways. *Scientific Report*. 2018;8:1-10.
51. Ogawa R, Okai K, Tokumura F, Mori K, Ohmori Y, Huang C, et al. The relationship between skin stretching/contraction and pathologic scarring : the important role of mechanical forces in keloid generation. *Wound Repair and Regeneration*. 2012;20:149-157.
52. Shih B, Garside E, Mcgrouther DA, Bayat A. Molecular dissection of abnormal wound healing processes resulting in keloid disease. *Wound Repair and Regeneration* 2010:139-153.
53. Kenny FN, Drymoussi Z, Delaine-smith R, Kao AP, Laly AC, Knight MM, et al. Tissue stiffening promotes keratinocyte proliferation through activation of epidermal growth factor signaling. 2018;131:1-10.
54. Lian N, Li T. Growth factor pathways in hypertrophic scars : molecular pathogenesis and therapeutic implications. *Biomedicine and Pharmacotherapy*. 2016;84:42-50.
55. Satish L, Evdokiou A, Geletu E, Hahn JM, Supp DM. Pirfenidone inhibits epithelial – mesenchymal transition in keloid keratinocytes. *Burns & Trauma*. 2020;8:1-11.
56. Nordin A, Chowdhury SR, Saim AB, Bt R, Idrus R. Effect of kelulut honey on the cellular dynamics of TGF β -induced epithelial to mesenchymal transition in primary human keratinocytes. *International Journal of Environmental Research and Public Health*. 2020;17:1-15.
57. Kuwahara H, Tosa M, Murakami M, Mohammad G, Ogawa R. Examination of epithelial mesenchymal transition in keloid tissue and possibility of keloid therapy target. *PRS Global Open*. 2016:1-7.
58. Huang C, Ogawa R. The vascular involvement in soft tissue fibrosis — lessons learned from pathological scarring. *International Journal of Molecular Science*. 2020;21:1-18.
59. Velazquez SP, Mendoza FA, Jimenez SA. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases. *Journal of Clinical Medicine*. 2016:1-22.
60. Pakyari M, Farrokhi A, Maharlooei MK, Ghahary A. Critical role of transforming growth factor beta in different phases of wound healing. *Advances in Wound Care*. 2013;2(5):215-224.
61. Valluru M, Staton CA, Reed MWR, Brown NJ. Transforming growth factor- β and endoglin signaling orchestrate wound healing. *Frontiers in Physiology*. 2011;2:1-12.

62. Finsson KW, Mclean S, Guglielmo GM Di, Philip A. Dynamics of Transforming Growth Factor Beta Signaling in Wound Healing and Scarring. 2013;2(5):195-214.
63. Ramakrishnan MK, Babu M, Mathivanan T, Jayaraman V. Scar biology : fibroblast the key modulator. Indian Journal of Burn. 2014;22(1):3-9.
64. Ashcroft KJ, Syed F, Bayat A. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. Plos One. 2013;8(11).
65. Xue M, Jackson CJ. Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Advances in wound care. 2018;4(3):119-136.
66. Messadi DV, Doung HS, Zhang Q, Kelly AP, Tuan TL, Reischenberger E. Activation of NFkB signal pathways in keloid fibroblasts. Archives of Dermatological Research. 2004:125-133.
67. Hui X, Cauley RLM, Zhang W. Elevated Interleukin-6 expression in keloid fibroblasts. Journal of Surgical Research. 2000;89:74-77.
68. Johnson BZ, Stevenson AW, Prele CM, Fear MW, Wood FM. The role of IL-6 in skin fibrosis and cutaneous wound healing. Biomedicines. 2020;8:1-18.
69. Ghazizadeh M. Essential role of IL-6 signaling pathway in keloid pathogenesis. Journal of Nippon Medical School. 2007;74:11-22.
70. Binic I. Keloids and Hypertrophic Scars. In: Katsambas AD, editors. European Handbook of Dermatological treatment. Berlin:Springer-verlag Berlin Heidelberg. 2015:455-464.
71. Salati SA. Keloid – an extensive review in the light of recent literature. Journal of Pakistan Association of Dermatologists. 2019;29(2):225-249.
72. Machan S, Ruiz A RL. Dermal hypertrophy. In: Bologna J, Schaffer J, Cerroni L, editors. Dermatology 4th edition. New York: Elsevier. 2018:1712-1718.
73. Huang C, Liu L, You Z, Du Y, Ogawa. Clinical and Pathological Diagnosis of Scar. In: Ogawa R, editor. Total Scar Management. 2020:83-95.
74. Yoo MG, Kim IH. Keloids and hypertrophic scars: characteristic vascular structures visualized by using dermoscopy. Annals of Dermatology. 2014;26(5):603-609.
75. Jumper N, Paus R, Bayat A. Functional histopathology of keloid disease. Histology and Histopathology. 2015;30:1033-1057.
76. Jiao H, Zhang T, Fan J, Xiao R. The superficial dermis may initiate keloid formation : histological analysis of the keloid dermis at different depths. Frontiers in Physiology. 2017;8:1-9.
77. Chu KO, Pang CCP. Pharmacokinetics and disposition of green tea catechins. In: Malangu N, editor. Pharmacokinetics and Adverse Effects of Drugs- Mechanism and Risk Factors. London: IntechOpen. 2018:17-36.
78. Isemura M. Catechin in human health and disease. Molecules. 2019;24(528):1-5.
79. Rahmawati N, Bakhtiar A, Putra DP. Isolasi katekin dari gambir (*Uncaria gambir* (Hunter). Roxb) untuk sediaan farmasi dan kosmetik. Jurnal Penelitian Farmasi Indonesia. 2012;1:6-10.
80. Gadkari PV, Balaraman M. Catechins : sources, extraction and encapsulation : a review. Food and Bioproducts Processing. 2014;93:122-138.

81. Damanik DDP, Surbakti N, Hasibuan R. Ekstraksi katekin dari daun gambir (*Uncaria gambir roxb*) dengan metode maserasi. *Jurnal Teknik Kimia USU*. 2014;3:10-14.
82. Reygaert WC. Green tea catechins: their use in treating and preventing infectious diseases. *BioMed Research International*. 2018:1-9.
83. Anggraini T, Neswati, Asben A. Mangampo: a traditional method from west sumatra to extract gambir from uncaria gambir. *Pakistan Journal of Nutrition*. 2019;18(2):146-152.
84. Zink A, Hoffmann CT. Green tea in dermatology-myths and facts. *Journal of the german Society of Dermatology*. 2015:768-775.
85. Klass BR, Branford OA, Grobbelaar AO, Rolfe KJ. The effect of epigallocatechin-3-gallate, a constituent of green tea, on transforming growth factor-1 β -stimulated wound contraction. *Wound Repair and Regeneration*. 2010;18:80-88.
86. Syed F, Bagabir RA, Paus R, Bayat A. Ex vivo evaluation of antifibrotic compounds in skin scarring: EGCG and silencing of PAI-1 independently inhibit growth and induce keloid shrinkage. *Laboratory Investigation*. 2013;93:946-960.
87. Sidgwick GP, Mc George D, Bayat DMA. Functional testing of topical skin formulations using an optimised ex vivo skin organ culture model. *Arch Dermatol Res*. 2016.
88. Amos. Kandungan katekin gambir sentra produksi di Indonesia. *Jurnal Standardisasi*. 2010;(3):149-155.
89. Andasuryani, Purwanto YA, Budiastira IW, Syamsu K. Prediksi kandungan katekin gambir (*Uncaria gambir Roxb*) dengan spektroskopi NIR. *Jurnal Teknologi Industri Pertanian*. 2014;24(1):43-52.
90. Marlinda. Identifikasi kadar katekin pada gambir (*Uncaria Gambier Roxb*). *Jurnal Optimalisasi*. 2018;4(1):47-53.
91. Isnawati A, Rainil M, Sampumo OD, Mutiatikum D, Widowati L, Gitawati R. Karakterisasi tiga jenis ekstrak gambir (*Uncaria gambir Roxb*) dari Sumatera Barat. *Buletin Penelitian Sistem Kesehatan*. 2012;40(4):201-208.
92. Aditya M, Ariyanti PR. Manfaat gambir (*Uncaria gambir Roxb*) sebagai antioksidan. *Majority*. 2016;5(3):129-133.
93. Aswardi, Iswari K, Harnel. Kajian mutu gambir di kabupaten Pesisir Selatan. *Balai Besar Penelitian dan Pengembangan Pascapanen Pertanian*. 2001:1192-1200.
94. Maulidian. Analisis perencanaan strategik bisnis katekin dan tanin – studi kasus: PT Gambir Agro Farmaka. *Jurnal Kesejahteraan Sosial*. 2015;2(2):158-170.
95. Nasrul W, Zulmardi, Indrayani TI. Kinerja Kelembagaan Pasar Gambir (*Uncaria Gambir Rox*). Kabupaten Solok: CV. Insan Cendekia mandiri. 2019.
96. Haris A, Asmarantaka RW, Baga LM. Efisiensi pemasaran gambir di Kabupaten Lima Puluh Kota, Sumatera Barat. *Buletin Ilmiah Litbang Perdagangan*. 2015;9(2):221-240.
97. Kurniatri AA, Sulistyaningrum N, Rustanti L. Purifikasi katekin dari ekstrak gambir (*Uncaria gambir Roxb*). *Media Litbangkes*. 2019;29(2):153-160.

98. Guruvayoorappan C, Kuttan G. (+)-Catechin inhibits tumour angiogenesis and regulates the production of nitric oxide and TNF- α in LPS-stimulated macrophages. *Innate Immunity*. 2008;114(3):160-174.
99. Al-hazzani AA, Alshatwi AA. Catechin hydrate inhibits proliferation and mediates apoptosis of SiHa human cervical cancer cells. *FOOD Chem Toxicol*. 2011;49(12):3281-3286.
100. Husein SSS, Kamarudin MNA, Kadir HA. (+)-Catechin attenuates NF-kB activation through regulation of Akt, MAPK, and AMPK signaling pathways in LPS-induced BV-2 microglial cells. *The American Journal of Chinese Medicine*. 2015;43(5):1-26.
101. Ud-Din S, Bayat A. Non-animal models of wound healing in cutaneous repair: in silico, invitro, exvivo and invivo models of wounds and scars in human skin. *Wound Repair and Regeneration*. 2015.
102. Kurniawati Y, Adi S, Achadiyani, Suwarsa O, Erlangga D, Putri T. Kultur primer fibroblas : penelitian pendahuluan. *Majalah Kedokteran Andalas*. 2015;38:33-40.
103. Sunaga A, Kamochi H, Sarukawa S, Uda H, Sugawara Y, Asahi R, et al. Reconstitution of human keloids in mouse skin. *PRS Global Open*. 2017:1-7.
104. Supp DM. Animal models for studies of keloid scarring. *Advances in Wound Care*. 2019;8(2):77-89.
105. Mangis JW, Mansur TB, Kern KM, Schroeder JR. Selection of an optimal cytotoxicity assay for undergraduate research. *Department of Biology*. 2019;45(1):24-32.
106. Yu Y, Deng Y, Lu BM, Liu YX, Li J, Bao JK. Green tea catechins: a fresh flavor to anticancer therapy. *Apoptosis*. 2014:1-18.
107. Vittorio O, Cirillo G, Lemma F, Turi GD, Jacchetti E, Curcio M dkk. Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. *Pharmaceutical Research*. 2012;29:2601-2614.
108. Leo N, Battaglini M, Berger L, Giannaccini M, Dente L, Hampel S dkk. A catechin nanoformulation inhibits WM266 melanoma cell proliferation, migration and associated neo-angiogenesis. *European Journal of Pharmaceutics and Biopharmaceutics*. 2017;114:1-10.
109. Weyant MJ, Carothers AM, Dannenberg AJ, Bertagnolli MM. (+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min +/- mouse 1. *Cancer Research*. 2001:118-125.
110. Makino S, Mitsutake N, Nakashima M, Saenko VA, Ohtsuru A, Umezawa K dkk. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. *Journal of Dermatological Science* 2008;51:171-180.
111. Lim CP, Phan T, Lim IJ, Cao X. STAT 3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. *Oncogene*. 2006:5416-5425.